Mohs micrographic surgery (MMS) is expanding surgical treatment options for melanoma. For more than 2 decades, National Comprehensive Cancer Network (NCCN) guidelines have recommended conventional wide local excision (WLE) with prescribed surgical margins for all cutaneous melanomas, regardless of anatomical location or histological subtype.1 Despite those recommendations, use of MMS for melanoma in the United States increased 304% from 2001 (2.6% of melanomas) to 2016 (7.9% of melanomas).2 Use of MMS for melanoma varies geographically in the United States, as does use of melanocytic immunohistochemical stains during MMS.2 Why is the use of MMS for melanoma growing? How do we develop best practices to reduce variations for this specialized technique?
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Miller CJ, Giordano CN, Higgins HW. Mohs Micrographic Surgery for Melanoma: As Use Increases, So Does the Need for Best Practices. JAMA Dermatol. Published online August 28, 2019. doi:10.1001/jamadermatol.2019.2589
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: